When do the ORUVAIL patents expire, and when will ORUVAIL go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms Inc	ORUVAIL	ketoprofen	CAPSULE, EXTENDED RELEASE;ORAL	019816-003	Feb 8, 1995		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Wyeth Pharms Inc	ORUVAIL	ketoprofen	CAPSULE, EXTENDED RELEASE;ORAL	019816-002	Feb 8, 1995		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Wyeth Pharms Inc	ORUVAIL	ketoprofen	CAPSULE, EXTENDED RELEASE;ORAL	019816-001	Sep 24, 1993		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 1, 2026

Oruvail is a mature ketoprofen extended-release NSAID with limited investment value as a branded pharmaceutical asset. Its commercial position is constrained by generic substitution, long-established safety warnings for nonsteroidal anti-inflammatory drugs, limited differentiation, and the absence of a meaningful current patent moat. The investment case depends on low-cost generic manufacturing, niche supply continuity, or portfolio acquisition rather than brand growth or exclusivity.

What is Oruvail and who owns the drug?

Oruvail is the brand name for ketoprofen extended-release capsules, an oral NSAID used for symptomatic treatment of rheumatoid arthritis and osteoarthritis. The product was developed and marketed in the United States by Wyeth-Ayerst Laboratories, later part of Wyeth and then Pfizer following Pfizer's acquisition of Wyeth in 2009.

Attribute	Oruvail
Active ingredient	Ketoprofen
Drug class	Nonsteroidal anti-inflammatory drug
Dosage form	Extended-release oral capsules
Historical strengths	100 mg, 150 mg, and 200 mg
U.S. regulatory application	NDA 019658
Therapeutic area	Osteoarthritis and rheumatoid arthritis
Regulatory pathway	New Drug Application
Current commercial position	Mature, largely genericized product
Reference innovator	Wyeth-Ayerst Laboratories
Primary competitive threat	Generic ketoprofen extended-release capsules

Oruvail is pharmacologically distinct from immediate-release ketoprofen products such as Orudis because the extended-release formulation is designed to provide prolonged drug exposure. The active ingredient itself is not compositionally novel by current standards. Any remaining commercial differentiation would therefore depend on formulation, manufacturing reliability, prescriber familiarity, or distribution.

When did Oruvail lose exclusivity?

Oruvail lost meaningful market exclusivity years ago. The product is no longer positioned as a protected branded innovation in the U.S. market.

The relevant exclusivity drivers were:

Expiration of the original product and formulation patent rights.
Approval of generic ketoprofen extended-release products.
Substitution pressure from lower-priced NSAIDs.
Broad availability of alternative therapies, including naproxen, ibuprofen, diclofenac, meloxicam, and celecoxib.

The key commercial point is that Oruvail has no current exclusivity period comparable to a new chemical entity, orphan drug, pediatric, or biologic product. FDA approval of generic versions removes the principal barrier to substitution. FDA's Orange Book identifies approved products and listed patent or exclusivity information, but a legacy product such as Oruvail does not have a current high-value exclusivity profile comparable to recently launched branded medicines (U.S. Food and Drug Administration, 2024a).

What patents protect Oruvail?

Oruvail's historical patent protection was directed primarily to ketoprofen extended-release delivery rather than to a new active pharmaceutical ingredient.

Patent estate characteristics

Patent category	Commercial relevance
Ketoprofen compound patents	Expired or commercially irrelevant
Extended-release formulation patents	Historical protection; no current branded moat
Manufacturing patents	Potentially relevant to process efficiency but unlikely to block generic competition broadly
Method-of-use patents	Limited value for a mature NSAID indication
Device patents	Not applicable to the capsule product
Biologic patents	Not applicable

The remaining value of any historical formulation patent would depend on its exact claims, expiration date, terminal disclaimers, PTA, and enforceability. Those factors do not create a material investment thesis for Oruvail today because generic competition has already established the product category.

A buyer evaluating a legacy ketoprofen extended-release asset would need to distinguish between:

An expired patent covering the active ingredient;
A formulation patent covering release characteristics;
A process patent covering a particular manufacturing method; and
A patent that could support a narrow infringement action against a specific generic product.

A formulation patent may support litigation against one manufacturing design without preventing alternative extended-release formulations. That distinction is important because a narrow formulation claim usually does not restore broad product exclusivity.

What is the FDA regulatory status of Oruvail?

Oruvail was approved as an NDA product for chronic inflammatory and degenerative joint conditions. Ketoprofen remains an established NSAID active ingredient, but the regulatory profile is mature rather than growth-oriented.

The FDA label warns of class risks associated with NSAIDs, including:

Cardiovascular thrombotic events;
Gastrointestinal bleeding, ulceration, and perforation;
Renal toxicity;
Hypertension and fluid retention;
Serious skin reactions;
Anaphylactoid reactions;
Fetal ductus arteriosus closure risk during later pregnancy.

The class-wide boxed warning for NSAIDs creates a ceiling on pricing and commercial expansion. It also limits the likelihood that a sponsor could reposition Oruvail as a premium chronic therapy without new clinical evidence or a materially differentiated delivery system (U.S. Food and Drug Administration, 2024b).

What is the Orange Book status of Oruvail?

Oruvail's Orange Book relevance is historical and regulatory rather than strategic. The key questions for an investor are whether the reference listed drug remains marketed, whether its NDA is active, whether any patents remain listed, and whether approved ANDAs remain commercially available.

A practical Orange Book review should examine:

Review item	Investment implication
NDA 019658 status	Determines whether the product remains an active reference product
Listed patents	Identifies any residual litigation rights
Exclusivity codes	Establishes whether any regulatory barrier remains
Approved ANDAs	Measures generic competition
Discontinued-product designation	Affects reference-product and ANDA strategy
Current marketing status	Indicates whether brand support remains

For a mature product such as Oruvail, an investor should not equate an active NDA with active commercial strength. An NDA can remain in FDA records even when the product has limited or no meaningful brand sales.

How many patents cover Oruvail today?

The relevant commercial answer is that Oruvail has no meaningful active patent estate that supports premium pricing or durable market exclusivity.

Any residual patent count should be separated into three categories:

Patents that have expired and have no blocking effect.
Patents listed historically but no longer enforceable because their terms ended.
Patents covering narrow manufacturing or formulation techniques that do not prevent alternative generic products.

A patent-count approach is misleading for Oruvail. One active process patent could be commercially irrelevant if competitors can manufacture the product through non-infringing processes. Conversely, one valid formulation patent could matter if all practical commercial alternatives infringe, but that scenario is unlikely for an established oral NSAID with generic precedent.

Which companies are challenging Oruvail's market position?

Generic manufacturers and low-cost suppliers, rather than branded innovators, define Oruvail's competitive landscape.

Potential competitors include suppliers of:

Generic ketoprofen extended-release capsules;
Immediate-release ketoprofen;
Naproxen;
Ibuprofen;
Diclofenac;
Meloxicam;
Celecoxib;
Topical NSAID products.

The competitive threat is broader than products containing the same active ingredient. Prescribers can select among multiple NSAIDs based on dosing frequency, gastrointestinal risk, cardiovascular profile, formulary status, and patient response.

Direct competitive comparison

Product or class	Main advantage versus Oruvail	Main disadvantage
Generic ketoprofen ER	Same active ingredient, lower price	Limited differentiation
Immediate-release ketoprofen	Flexible dosing, established supply	More frequent administration
Naproxen	Broad availability and low cost	NSAID class safety risks
Meloxicam	Once-daily dosing and chronic-use familiarity	Generic competition and class warnings
Celecoxib	COX-2 selectivity and differentiated prescribing profile	Cardiovascular and pricing concerns
Topical diclofenac	Lower systemic exposure for selected conditions	Limited suitability for widespread or deep joint pain

What generic entry risks exist for Oruvail?

Generic substitution risk is high. The active ingredient is old, the dosage form is conventional, and the principal indications are established. Generic manufacturers do not need to fund the clinical development program required for a novel therapy. They generally need to demonstrate pharmaceutical equivalence and bioequivalence under the applicable ANDA framework.

Generic launch scenarios

Scenario	Probability profile	Commercial impact
Continued low-volume generic supply	High	Maintains price pressure and limits brand recovery
Additional generic entrants	Moderate	Further reduces pricing and market share
Brand relaunch at premium price	Low	Requires differentiation not evident in the current product
Reformulated extended-release product	Low to moderate	Could create a niche if it improves tolerability or adherence
Product withdrawal because of low demand	Possible	Reduces commercial value but may create supply-constrained niche pricing

The strongest generic barriers would be manufacturing complexity, limited API supply, or difficult bioequivalence requirements. Ketoprofen extended-release capsules may require controlled-release formulation expertise, but those barriers are not equivalent to a modern complex drug-device or long-acting injectable barrier.

Is there Paragraph IV litigation involving Oruvail?

Paragraph IV litigation would have been most relevant when generic applicants first challenged listed patents. For a legacy Oruvail product, the principal litigation window has passed.

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. If the reference sponsor files suit within the statutory period, FDA approval of the ANDA can be stayed for up to 30 months, subject to statutory exceptions and court developments (U.S. Food and Drug Administration, 2024c).

The current investment significance is limited:

Any original formulation litigation is historical.
A new Paragraph IV event would require a currently listed, unexpired patent.
A narrow process patent would have less blocking power than a composition or formulation patent.
Generic entry would remain the base-case commercial outcome absent an enforceable patent or regulatory exclusivity.

What patent litigation affects Oruvail?

No current high-value litigation thesis is apparent for Oruvail. The product does not have the characteristics that typically generate sustained pharmaceutical patent disputes: a large branded revenue base, a recently approved formulation, a high-value biologic, or a complex delivery platform.

Historical or potential disputes would focus on:

Bioequivalence of extended-release formulations;
Release-rate specifications;
Capsule dissolution profiles;
Manufacturing processes;
Labeling for chronic inflammatory conditions.

For investment purposes, litigation should be treated as a tail event rather than a central valuation driver.

Are there biosimilar risks for Oruvail?

No. Oruvail is a small-molecule drug, not a biologic. Biosimilar pathways under the Public Health Service Act do not apply.

The relevant regulatory competition is generic competition under the Federal Food, Drug, and Cosmetic Act. This distinction matters because biosimilar products often face higher development and manufacturing barriers than conventional small-molecule generics. Oruvail does not benefit from those biologic-style barriers.

Are there licensing deals involving Oruvail?

Oruvail's historical commercialization was associated with Wyeth-Ayerst and later Pfizer's product portfolio. There is no apparent current licensing structure that gives the product strategic value comparable to an actively promoted co-commercialized medicine.

A transaction involving Oruvail would more likely be structured as:

A mature-product portfolio acquisition;
A regional marketing license;
A generic or authorized-generic supply agreement;
A manufacturing and distribution transfer; or
A rights package bundled with other established products.

A standalone license would require a credible supply, distribution, or formulation rationale. Brand rights alone would be weak because prescribers and payers can substitute generic NSAIDs.

How strong is the Oruvail patent estate?

Oruvail's patent estate is weak from an investment perspective.

Patent-strength factor	Assessment
Composition-of-matter protection	None of current strategic value
Remaining regulatory exclusivity	None of material commercial value
Formulation protection	Historical and potentially narrow
Generic substitution resistance	Low
Litigation leverage	Low
Manufacturing barriers	Moderate at most
Pricing power	Low
Geographic exclusivity	Limited and jurisdiction-specific
Renewal or lifecycle potential	Dependent on new formulation development

The product could have niche value in markets where ketoprofen remains preferred or where local supply is unreliable. That is a distribution thesis, not a patent thesis.

What revenue exposure does Oruvail create?

Oruvail's standalone revenue is not a reliable public valuation metric because the product has been part of a large corporate portfolio and is not generally reported as a separate material revenue line.

Revenue exposure is therefore best modeled through operating assumptions:

Variable	Base assessment
Brand price	Low to moderate, depending on market
Generic price erosion	High
Volume growth	Flat to declining
Prescriber loyalty	Limited
Payer preference	Strongly generic-oriented
Promotion requirement	Low, but promotion would have weak returns
Supply-chain value	Potentially meaningful in selected markets
Margin potential	Dependent on manufacturing cost and competition

A manufacturer could generate acceptable returns if it has low-cost API access, existing capsule capacity, established regulatory approvals, and efficient distribution. The asset does not support a conventional branded-pharmaceutical valuation based on future exclusivity.

What geographic markets could support Oruvail?

Geographic value depends on national approval status, patent expiry, generic penetration, prescription practices, and local NSAID demand.

Potentially attractive markets would have:

Continued use of ketoprofen;
Limited generic competition;
Favorable reimbursement;
Local manufacturing advantages;
Reliable API access;
A distribution network serving rheumatology, orthopedics, or primary care.

The United States is unlikely to offer strong branded economics. Other markets may support a low-cost generic or licensed product, but geographic rights must be assessed country by country because patent, regulatory, and marketing statuses do not transfer automatically across jurisdictions.

What manufacturing and intellectual-property barriers remain?

The main operational risk is not patent infringement. It is consistent production of an extended-release dosage form that meets dissolution, stability, content uniformity, and bioequivalence requirements.

Manufacturing diligence should focus on:

Ketoprofen API sourcing;
Granulation and coating technology;
Modified-release excipients;
Dissolution-profile control;
Stability in target climates;
Capsule-filling capacity;
FDA and other agency inspection history;
Supplier concentration;
ANDA or local-market approval status.

These barriers may protect a reliable supplier from short-term competition, but they are unlikely to create durable market exclusivity.

What is the investment scenario for Oruvail?

Bull case

The bull case is a niche supply opportunity. A manufacturer acquires or licenses rights in a market where ketoprofen remains widely prescribed, secures low-cost API supply, and avoids direct competition through dependable availability. Margins could be acceptable if the product is sold as part of a broader generic portfolio.

Base case

The base case is a mature, low-growth generic product with price pressure and limited brand relevance. Revenue is stable only where the manufacturer has established distribution or temporary supply advantages. Valuation is based on manufacturing cash flow, not intellectual property.

Bear case

The bear case is continued substitution by generic ketoprofen and other NSAIDs, withdrawal of the branded product, declining reimbursement, or manufacturing interruption. A new branded investment would fail to recover development and promotional costs without a differentiated formulation or new clinical positioning.

Key Takeaways

Oruvail is a mature ketoprofen extended-release NSAID, not a protected growth asset.
Its original exclusivity has expired, and generic competition is the central commercial factor.
The product has no biologic or biosimilar exposure.
Any remaining formulation or process patents are unlikely to provide broad market protection.
Paragraph IV and patent litigation are historical or low-probability issues rather than current valuation drivers.
Standalone Oruvail revenue is not a meaningful publicly reported metric.
The strongest investment case is a low-cost generic, regional licensing, or supply-continuity strategy.
A branded relaunch would carry substantial commercial risk because alternative NSAIDs are widely available.

FAQs About Oruvail Patent and Investment Risk

Is Oruvail still marketed in the United States?

Oruvail has limited commercial relevance in the United States compared with generic ketoprofen and competing NSAIDs. FDA application records should be distinguished from active brand promotion or material branded sales.

Is ketoprofen extended-release still available as a generic?

Generic availability depends on manufacturer, dosage strength, market, and current supply conditions. Approved generic products, where marketed, remove the central exclusivity advantage of the Oruvail brand.

Could a new Oruvail formulation obtain patent protection?

Yes, a materially new extended-release system, combination product, or delivery technology could receive patents if it satisfies novelty, non-obviousness, written-description, and enablement requirements. Such patents would protect the new formulation, not automatically restore protection for legacy Oruvail.

Does Oruvail have a 30-month Paragraph IV stay?

A 30-month stay applies only when statutory conditions are met, including a qualifying ANDA challenge and timely patent litigation by the reference sponsor. It is not a permanent product-level protection and would require a relevant unexpired listed patent.

Is Oruvail a potential acquisition target?

It could be included in a mature-products or generic portfolio transaction. Its standalone value would likely depend on regulatory approvals, manufacturing economics, regional demand, and supply reliability rather than on patent exclusivity.

References

U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (2024b). Ketoprofen extended-release capsules prescribing information. FDA labeling database.
U.S. Food and Drug Administration. (2024c). Paragraph IV certification. FDA, Generic Drug User Fee Amendments resources. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/paragraph-iv-certifications
U.S. Food and Drug Administration. (2024d). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

ORUVAIL Drug Patent Profile

When do Oruvail patents expire, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Oruvail

AI Deep Research

Questions you can ask:

Summary for ORUVAIL

US Patents and Regulatory Information for ORUVAIL

Oruvail Investment Analysis: Ketoprofen Extended-Release Patent, Market, and Generic Risk